Purple Biotech Ltd. announced the appointment of Dr. Yael Margolin as an independent member of the Company's Board of Directors. Dr. Yael Margolin has more than 35 years of experience as senior manager, chief executive officer and board member in venture capital and in the pharmaceutical and biotech industries, leading strategic and business planning, financing, team building, product development and corporate partnerships. Since 2019, Dr. Margolin has served as a board member to several public and private companies in the healthtech industry, including: Point Biopharma Global, Scinai Immunotherapeutics, Quris AI, MakeSense, Neovac, Welltech Ventures, Ramot at Tel Aviv University and TAU Ventures by Tel Aviv University.

Dr. Margolin is a founder of mentoring@8400, a boutique voluntary mentoring program for young CEOs in Israel. From 2005 to 2019, she served as President, Chief Executive Officer and director of Gamida Cell Ltd. Prior to that, Dr. Margolin served as Vice President of Denali Ventures LLC, a venture capital firm focused on healthcare, and a program manager at Teva Pharmaceuticals. Dr. Margolin holds a B.Sc.

degree in biology and a M.Sc. degree Cum Laude both from Tel Aviv University in Israel, a Ph.D. from the Weitzman Institute of Science in Israel and was a post-doctoral associate at the Yale University School of Medicine. In addition, Purple announces that Mr. Fabien Sebille, who served as the Company's Chief Business Officer, resigned from such position to pursue other opportunities as of the end of November 2023.